Ideaya Biosciences Inc (IDYA)

09:36 AM

IDEAYA to present phase 2 data on uveal melanoma drug at ESMO By Investing.com - Investing.com South Africa

09:36 AM

09:25 AM

IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma - Yahoo Finance

09:25 AM

Jul 23, 2025

What drives IDEAYA Biosciences Inc. stock priceRobust financial gains - Autocar Professional

Jul 23, 2025

Jul 23, 2025

What analysts say about IDEAYA Biosciences Inc. stockFree Investment Portfolio Suggestions - Autocar Professional

Jul 23, 2025

Jul 23, 2025

IDEAYA Biosciences: Precision Oncology Pipeline and Synthetic Lethality Catalysts - AInvest

Jul 23, 2025

Jul 23, 2025

IDEAYA's First-in-Class Cancer Pipeline: Major Clinical Updates Coming at 10th Anniversary R&D Day - Stock Titan

Jul 23, 2025

Jul 23, 2025

Signaturefd LLC Increases Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World

Jul 23, 2025

Jul 23, 2025

IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC - The Malaysian Reserve

Jul 23, 2025

Jul 23, 2025

Is IDEAYA Biosciences Inc. a good long term investmentRobust financial gains - jammulinksnews.com

Jul 23, 2025

Jul 23, 2025

IDEAYA Biosciences Inc. Stock Analysis and ForecastHigh-margin investment plays - jammulinksnews.com

Jul 23, 2025

Jul 22, 2025

Breakthrough Lung Cancer Drug IDE849 Shows First Human Results: 70+ Patient Data Coming at WCLC 2025 - Stock Titan

Jul 22, 2025

Jul 22, 2025

Melanoma Market Anticipates a Dynamic Shift During the Forecast Period (2025–2034) Owing to the Strong Pipeline Activity | DelveInsight - GlobeNewswire Inc.

Jul 22, 2025

Jul 22, 2025

symbol__ Stock Quote Price and Forecast - CNN

Jul 22, 2025

Jul 22, 2025

IDEAYA Biosciences: TD Cowen initiates coverage with Buy rating. - AInvest

Jul 22, 2025

Jul 22, 2025

Promising Pipeline and Strategic Focus Drive Buy Rating for IDEAYA Biosciences - TipRanks

Jul 22, 2025

Jul 22, 2025

TD Cowen initiates Ideaya Biosciences stock with Buy rating By Investing.com - Investing.com Canada

Jul 22, 2025

Jul 21, 2025

autocarpro> 2025> What analysts say about IDEAYA Biosciences Inc. stockPhenomenal trading returns - Autocar Professional

Jul 21, 2025

Jul 21, 2025

IDEAYA Biosciences CEO Fireside Chat: Precision Medicine Updates at BTIG Conference - Stock Titan

Jul 21, 2025

Jul 19, 2025

Teacher Retirement System of Texas Cuts Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World

Jul 19, 2025

Jul 16, 2025

(IDYA) Proactive Strategies - news.stocktradersdaily.com

Jul 16, 2025

Jul 15, 2025

Why IDEAYA Biosciences Inc. stock attracts strong analyst attentionROI Driven Alerts - Newser

Jul 15, 2025

Jul 15, 2025

How IDEAYA Biosciences Inc. stock performs during market volatilityDaily Stock Radar - Newser

Jul 15, 2025

Jul 14, 2025

Brokerages Set IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Target Price at $47.55 - Defense World

Jul 14, 2025

Jul 12, 2025

The Goldman Sachs Group Upgrades IDEAYA Biosciences (NASDAQ:IDYA) to “Hold” - Defense World

Jul 12, 2025

Jul 11, 2025

IDEAYA Biosciences (NASDAQ:IDYA) Stock Rating Upgraded by Royal Bank Of Canada - Defense World

Jul 11, 2025

Jul 11, 2025

Ideaya Biosciences stock gets Neutral rating from Goldman Sachs By Investing.com - Investing.com Canada

Jul 11, 2025

Jul 10, 2025

Ideaya Biosciences price target lowered to $30 from $57 at RBC Capital - MSN

Jul 10, 2025

Jul 10, 2025

Ideaya Biosciences shares fall 2.68% intraday as Biocytogen Pharmaceuticals enters into a global licensing agreement with BeOne Medicines. - AInvest

Jul 10, 2025

Jul 10, 2025

RBC Capital Initiates IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $30 - 富途牛牛

Jul 10, 2025

Jul 09, 2025

Ideaya Biosciences stock price target lowered to $30 by RBC Capital - Investing.com Canada

Jul 09, 2025